#METABOLOMICS WORKBENCH michaelsa93_20170628_124602 DATATRACK_ID:1105 STUDY_ID:ST000659 ANALYSIS_ID:AN001005
VERSION             	1
CREATED_ON             	June 29, 2017, 11:33 am
#PROJECT
PR:PROJECT_TITLE                 	Changes in metabolites and lipid mediators associated with supervised exercise
PR:PROJECT_TITLE                 	training for peripheral artery disease
PR:PROJECT_SUMMARY               	Peripheral artery disease (PAD) is a leading cause of cardiovascular related
PR:PROJECT_SUMMARY               	morbidity and mortality, affecting over 8.5 million men and women in the United
PR:PROJECT_SUMMARY               	States and greater than 200 million individuals worldwide. The mainstay of
PR:PROJECT_SUMMARY               	treatment to improve lower limb symptoms is supervised walking therapy, which
PR:PROJECT_SUMMARY               	does not affect plaque morphology or alter conduit artery blood flow, but rather
PR:PROJECT_SUMMARY               	ameliorates endothelial dysfunction, enhances skeletal muscle metabolism and
PR:PROJECT_SUMMARY               	mitochondrial function, and suppresses inflammatory activation. In this pilot
PR:PROJECT_SUMMARY               	feasibility project we will employ metabolic and lipidomic techniques to measure
PR:PROJECT_SUMMARY               	the effects of supervised exercise therapy on primary metabolism, complex
PR:PROJECT_SUMMARY               	lipids, and lipid mediators, and correlate these effects with individual,
PR:PROJECT_SUMMARY               	subject-level measures of the response to exercise therapy among subjects with
PR:PROJECT_SUMMARY               	PAD. The overarching theme of this work is to identify metabolites, complex
PR:PROJECT_SUMMARY               	lipids, and lipid mediators that are associated with the inter-individual
PR:PROJECT_SUMMARY               	variability in the response of subjects with PAD to supervised exercise therapy.
PR:PROJECT_SUMMARY               	This knowledge will significantly enhance our understanding of the
PR:PROJECT_SUMMARY               	pathophysiology of lower extremity symptoms in PAD, as well as the manner in
PR:PROJECT_SUMMARY               	which supervised exercise therapy improves walking intolerance. It will identify
PR:PROJECT_SUMMARY               	novel therapeutic targets and pathways for pharmacologic manipulation in the
PR:PROJECT_SUMMARY               	treatment of PAD. Aside from having the potential to generate multiple
PR:PROJECT_SUMMARY               	high-impact publications, it will serve as the basis for a planned NIH R01
PR:PROJECT_SUMMARY               	submission by the PI at the conclusion of the award period.
PR:INSTITUTE                     	Perelman School of Medicine at University of Pennsylvania
PR:DEPARTMENT                    	Surgery
PR:LAST_NAME                     	Scott
PR:FIRST_NAME                    	Damrauer
PR:ADDRESS                       	3400 Spruce Street, 4 Silverstein Philadelphia, PA 19104
PR:EMAIL                         	Scott.Damrauer@uphs.upenn.edu
PR:PHONE                         	215-615-1698
#STUDY
ST:STUDY_TITLE                   	Changes in metabolites and lipid mediators associated with supervised exercise
ST:STUDY_TITLE                   	training for peripheral
ST:STUDY_TYPE                    	Timecourse
ST:STUDY_SUMMARY                 	Peripheral artery disease (PAD) is a leading cause of cardiovascular related
ST:STUDY_SUMMARY                 	morbidity and mortality, affecting over 8.5 million men and women in the United
ST:STUDY_SUMMARY                 	States and greater than 200 million individuals worldwide. The mainstay of
ST:STUDY_SUMMARY                 	treatment to improve lower limb symptoms is supervised walking therapy, which
ST:STUDY_SUMMARY                 	does not affect plaque morphology or alter conduit artery blood flow, but rather
ST:STUDY_SUMMARY                 	ameliorates endothelial dysfunction, enhances skeletal muscle metabolism and
ST:STUDY_SUMMARY                 	mitochondrial function, and suppresses inflammatory activation. In this pilot
ST:STUDY_SUMMARY                 	feasibility project we will employ metabolic and lipidomic techniques to measure
ST:STUDY_SUMMARY                 	the effects of supervised exercise therapy on primary metabolism, complex
ST:STUDY_SUMMARY                 	lipids, and lipid mediators, and correlate these effects with individual,
ST:STUDY_SUMMARY                 	subject-level measures of the response to exercise therapy among subjects with
ST:STUDY_SUMMARY                 	PAD. The overarching theme of this work is to identify metabolites, complex
ST:STUDY_SUMMARY                 	lipids, and lipid mediators that are associated with the inter-individual
ST:STUDY_SUMMARY                 	variability in the response of subjects with PAD to supervised exercise therapy.
ST:STUDY_SUMMARY                 	This knowledge will significantly enhance our understanding of the
ST:STUDY_SUMMARY                 	pathophysiology of lower extremity symptoms in PAD, as well as the manner in
ST:STUDY_SUMMARY                 	which supervised exercise therapy improves walking intolerance. It will identify
ST:STUDY_SUMMARY                 	novel therapeutic targets and pathways for pharmacologic manipulation in the
ST:STUDY_SUMMARY                 	treatment of PAD. Aside from having the potential to generate multiple
ST:STUDY_SUMMARY                 	high-impact publications, it will serve as the basis for a planned NIH R01
ST:STUDY_SUMMARY                 	submission by the PI at the conclusion of the award period.
ST:INSTITUTE                     	USDA
ST:DEPARTMENT                    	Obesity and metabolism research unit
ST:LAST_NAME                     	Newman
ST:FIRST_NAME                    	John
ST:ADDRESS                       	430 West Health Sciences Dr. Davis, Ca, 95616
ST:EMAIL                         	john.newman@ars.usda.gov
ST:PHONE                         	(530) 752-1009
ST:STUDY_COMMENTS                	Fatty acids measured but not against a calibration curve. Therefore values are
ST:STUDY_COMMENTS                	expressed as a relative abundance of the entire samples set such that the sum of
ST:STUDY_COMMENTS                	all subjects eguals 100%.
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
SU:GENDER                        	Male
SU:SUBJECT_COMMENTS              	Individuals with peripheral arterial disease, as defined by ankle brachial
SU:SUBJECT_COMMENTS              	indices ≥0.4 and ≤0.8 and the presence of classic claudication symptoms
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	P1 A01	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 B01	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 C01	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 D01	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 E01	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 F01	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 G01	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 H01	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 A02	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 B02	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 C02	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 D02	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 E02	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 F02	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 G02	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 H02	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 A03	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 B03	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 C03	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 D03	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 H03	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 A04	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 B04	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 C04	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 D04	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 E04	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 F04	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 G04	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 H04	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 A05	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 B05	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 C05	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 D05	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 E05	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 F05	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 G05	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 H05	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 A06	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 B06	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 C06	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 G06	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 H06	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 A07	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 B07	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 C07	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 D07	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 E07	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 F07	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 G07	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 H07	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 A08	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 B08	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 C08	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 D08	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 E08	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 F08	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 G08	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 H08	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 A09	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 B09	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 F09	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 G09	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 H09	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 A10	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 B10	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 C10	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 D10	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 E10	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 F10	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 G10	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 H10	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 A11	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 B11	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 C11	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 D11	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 E11	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 F11	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 G11	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 H11	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 A12	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 E12	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 F12	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P1 G12	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P1 H12	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 A01	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 B01	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 C01	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 D01	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 E01	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 F01	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 G01	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 H01	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 A02	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 B02	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 C02	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 D02	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 E02	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 F02	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 G02	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 H02	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 D03	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 E03	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 F03	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 G03	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 H03	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 A04	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 B04	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 C04	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 D04	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 E04	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 F04	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 G04	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 A05	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 B05	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 C05	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 D05	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 E05	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 F05	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 G05	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 C06	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 D06	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 E06	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 F06	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 G06	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 H06	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 A07	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 B07	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 C07	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 D07	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 E07	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 F07	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 G07	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 H07	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 A08	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 B08	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 C08	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 D08	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 E08	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 F08	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 B09	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 C09	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 D09	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 E09	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 F09	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 G09	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 H09	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 A10	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 B10	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 C10	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 D10	Visit:v2 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 E10	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 F10	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 G10	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 H10	Visit:v2 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 A11	Visit:v3 | Blood Draw:A	
SUBJECT_SAMPLE_FACTORS           	-	P2 B11	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 C11	Visit:v3 | Blood Draw:B	
SUBJECT_SAMPLE_FACTORS           	-	P2 D11	Visit:v2 | Blood Draw:A	
#COLLECTION
CO:COLLECTION_SUMMARY            	Blood was drawn form the subject at the baseline (Visit 2 (V2)) before (B) and
CO:COLLECTION_SUMMARY            	after (A) the treadmill exercise test. Further, blood was collected after 12
CO:COLLECTION_SUMMARY            	weeks of supervised walking therapy (Visit 3 (V3)), before (B) and after (A) the
CO:COLLECTION_SUMMARY            	treadmill exercise test.
CO:SAMPLE_TYPE                   	Plasma
#TREATMENT
TR:TREATMENT_SUMMARY             	Subjects with peripheral arterial disease, as defined by ankle brachial indices
TR:TREATMENT_SUMMARY             	≥0.4 and ≤0.8 and the presence of classic claudication symptom were
TR:TREATMENT_SUMMARY             	subjected to the treadmill exercise test. Further, they underwent 12 weeks of
TR:TREATMENT_SUMMARY             	supervised walking therapy and subjected to the treadmill exercise test again.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Lipid mediator extraction and quantification: Oxylipins, endocannabinoids, and
SP:SAMPLEPREP_SUMMARY            	fatty acids were isolated from plasma using Ostro Sample Preparation Plates
SP:SAMPLEPREP_SUMMARY            	(Waters; Milford, MA) in the presence of BHT/EDTA and quantified by UPLC-MS/MS
SP:SAMPLEPREP_SUMMARY            	using internal standard methods. Briefly, in the Ostro Plate well, 100µl plasma
SP:SAMPLEPREP_SUMMARY            	aliquots were mixed with 5µl of BHT/EDTA (1:1 v/v MeOH/water) and 5µl methanol
SP:SAMPLEPREP_SUMMARY            	containing a suite of deuterated surrogates. The samples were then mixed with
SP:SAMPLEPREP_SUMMARY            	300µL of acetonitrile with 1% formic acid and eluted with 15 mmHg vacuum for 10
SP:SAMPLEPREP_SUMMARY            	min into 200µL glass inserts containing 10µl of 20% glycerol in methanol.
SP:SAMPLEPREP_SUMMARY            	Solvent was removed by vacuum centrifugation and the glycerol plug was stored at
SP:SAMPLEPREP_SUMMARY            	-80Co until analysis. Prior acquisition, samples were reconstituted in 100µl of
SP:SAMPLEPREP_SUMMARY            	1:1 methanol:acetonitrile containing 100nM of 1-cyclohexyl ureido, 3-dodecanoic
SP:SAMPLEPREP_SUMMARY            	acid (CUDA) and 1-phenyl ureido, 3-hexadecanoic acid (PUHA). Residues within
SP:SAMPLEPREP_SUMMARY            	extracts were separated on a 2.1 x 150mm 0.17µm BEH column (Waters) and
SP:SAMPLEPREP_SUMMARY            	detected by electrospray ionization with multi reaction monitoring on a API 6500
SP:SAMPLEPREP_SUMMARY            	QTRAP (Sciex; Redwood City, CA) and quantified against 7-9 point calibration
SP:SAMPLEPREP_SUMMARY            	curves of authentic standards using modifications of previously reported methods
SP:SAMPLEPREP_SUMMARY            	(Grapov, D., et al. 2012. PLoS One 7: e48852.; doi:
SP:SAMPLEPREP_SUMMARY            	10.1371/journal.pone.0048852).
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE        	Reversed phase
CH:INSTRUMENT_NAME            	Waters Acquity UPLC
CH:COLUMN_NAME                	Acquity UPLC BEH C18 1.7μm 2.1 × 100 mm column
CH:FLOW_GRADIENT              	See protocol/methods file
CH:FLOW_RATE                  	0.25 uL
CH:COLUMN_TEMPERATURE         	60 °C
CH:METHODS_FILENAME           	2017_6500_OxyEndo_Analysis_protocol.pdf
CH:SOLVENT_A                  	0.1% acetic acid
CH:SOLVENT_B                  	90% ACN / 10% IPA
CH:INTERNAL_STANDARD          	See protocol/methods file
CH:RETENTION_TIME             	See protocol/methods file
CH:SAMPLE_INJECTION           	5 µL
CH:ANALYTICAL_TIME            	20 min
CH:WEAK_WASH_SOLVENT_NAME     	20% methanol, 10% isopropanol
CH:WEAK_WASH_VOLUME           	600 µL
CH:STRONG_WASH_SOLVENT_NAME   	50:50 Acetonitrile:Methanol
CH:STRONG_WASH_VOLUME         	600 µL
#ANALYSIS
AN:ANALYSIS_TYPE            	MS
AN:LABORATORY_NAME          	Newman
AN:OPERATOR_NAME            	Kamil Borkowski
AN:SOFTWARE_VERSION         	AB Sciex MultiQuant version 3.0.1
#MS
MS:INSTRUMENT_NAME          	Waters Acquity UPLC
MS:INSTRUMENT_TYPE          	API 6500 QTrap
MS:MS_TYPE                  	ESI
MS:ION_MODE                 	POSITIVE
MS:MS_COMMENTS              	Endocannabinoid Analysis
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	Concentration pmol/g
MS_METABOLITE_DATA_START
Samples	P1 A01	P1 B01	P1 C01	P1 D01	P1 E01	P1 F01	P1 G01	P1 H01	P1 A02	P1 B02	P1 C02	P1 D02	P1 E02	P1 F02	P1 G02	P1 H02	P1 A03	P1 B03	P1 C03	P1 D03	P1 H03	P1 A04	P1 B04	P1 C04	P1 D04	P1 E04	P1 F04	P1 G04	P1 H04	P1 A05	P1 B05	P1 C05	P1 D05	P1 E05	P1 F05	P1 G05	P1 H05	P1 A06	P1 B06	P1 C06	P1 G06	P1 H06	P1 A07	P1 B07	P1 C07	P1 D07	P1 E07	P1 F07	P1 G07	P1 H07	P1 A08	P1 B08	P1 C08	P1 D08	P1 E08	P1 F08	P1 G08	P1 H08	P1 A09	P1 B09	P1 F09	P1 G09	P1 H09	P1 A10	P1 B10	P1 C10	P1 D10	P1 E10	P1 F10	P1 G10	P1 H10	P1 A11	P1 B11	P1 C11	P1 D11	P1 E11	P1 F11	P1 G11	P1 H11	P1 A12	P1 E12	P1 F12	P1 G12	P1 H12	P2 A01	P2 B01	P2 C01	P2 D01	P2 E01	P2 F01	P2 G01	P2 H01	P2 A02	P2 B02	P2 C02	P2 D02	P2 E02	P2 F02	P2 G02	P2 H02	P2 D03	P2 E03	P2 F03	P2 G03	P2 H03	P2 A04	P2 B04	P2 C04	P2 D04	P2 E04	P2 F04	P2 G04	P2 A05	P2 B05	P2 C05	P2 D05	P2 E05	P2 F05	P2 G05	P2 C06	P2 D06	P2 E06	P2 F06	P2 G06	P2 H06	P2 A07	P2 B07	P2 C07	P2 D07	P2 E07	P2 F07	P2 G07	P2 H07	P2 A08	P2 B08	P2 C08	P2 D08	P2 E08
Factors	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:A	Visit:v2 | Blood Draw:B	Visit:v3 | Blood Draw:B	Visit:v2 | Blood Draw:A	Visit:v3 | Blood Draw:B	Visit:v3 | Blood Draw:A
LEA	2	2.06	2.05	2.22	1.67	1.68	1.88	2.56	1.78	1.71	2.41	1.37	3.32	2.82	2.49	1.9	1.07	1.75	2.79	3.34	4.34	3.73	3.25	1.06	3.75	2.96	3.41	2.14	1.91	1.31	2.01	1.36	1.03	2.81	3.86	1.83	1.58	1.64	1.7	2.07	1.34	3.18	1.46	1.93	2.08	2.84	3.15	1.28	3.86	1.82	2.54	1.32	2.59	1.71	2.63	1.99	1.67	2.07	0.905	5.1	1.58	2.8	1.81	1.85	3.68	1.57	1.26	1.45	2.24	1.71	3.05	1.54	3.13	2.56	2.57	1.28	3.05	2.21	2.6	3.7	1.62	2.71	1.18	2.18	2.67	2.05	1.39	2.04	2.62	1.29	1.84	2.29	3.24	2.77	1.26	3.24	2.15	1.91	2.18	1.72	1.91	1.61	2.12	1.26	2.12	1.18	2.1	1.77	3	1.7	1.12	1.76	1.87	1.83	2.38	2	2.23	2.09	2.02	1.76	2.35	1.78	1.23	2.16	1.28	4.17	2.84	1.32	1.25	4.8	2.71	2.01	1.12	2.41	2.32	1.3	1.38	1.72
aLEA	0.129	0.0885	0.101	0.0607	0.0701	0.0614	0.0787	0.0919	0.0664	0.0677	0.118	0.0509	0.183	0.101	0.125	0.0833	0.0518	0.0552	0.0809	0.176	0.244	0.163	0.171	0.0281	0.138	0.135	0.156	0.119	0.0631	0.0576	0.0634	0.0452	0.0129	0.135	0.204	0.101	0.049	0.0618	0.0565	0.0749	0.0524	0.131	0.0978	0.0926	0.104	0.122	0.2	0.0658	0.146	0.0699	0.114	0.0539	0.16	0.0891	0.107	0.0791	0.0469	0.0618	0.0312	0.253	0.0591	0.121	0.0617	0.104	0.161	0.0784	0.0491	0.0637	0.0912	0.0638	0.172	0.0738	0.182	0.116	0.078	0.073	0.0806	0.0612	0.0903	0.151	0.0577	0.138	0.0498	0.0331	0.18	0.0907	0.0685	0.0854	0.113	0.0678	0.0516	0.0677	0.103	0.0988	0.0474	0.131	0.0774	0.0798	0.095	0.0502	0.061	0.058	0.11	0.0381	0.0804	0.0537	0.0725	0.0765	0.0953	0.0504	0.0601	0.0588	0.0796	0.0909	0.106	0.0698	0.0734	0.0767	0.109	0.103	0.141	0.0947	0.0382	0.103	0.0509	0.222	0.24	0.0984	0.0412	0.215	0.109	0.0908	0.051	0.107	0.125	0.0644	0.0567	0.129
DGLEA	0.271	0.222	0.256	0.249	0.156	0.161	0.13	0.271	0.249	0.136	0.234	0.155	0.217	0.238	0.226	0.171	0.0782	0.165	0.242	0.233	0.305	0.376	0.241	0.23	0.304	0.362	0.241	0.213	0.156	0.156	0.289	0.152	0.181	0.192	0.256	0.157	0.198	0.141	0.158	0.144	0.122	0.283	0.194	0.256	0.286	0.32	0.22	0.118	0.257	0.253	0.171	0.121	0.191	0.114	0.156	0.237	0.171	0.231	0.174	0.416	0.127	0.187	0.195	0.163	0.235	0.143	0.163	0.259	0.247	0.215	0.238	0.23	0.117	0.186	0.224	0.179	0.185	0.218	0.359	0.401	0.139	0.273	0.182	0.212	0.31	0.241	0.241	0.245	0.295	0.149	0.312	0.223	0.418	0.286	0.175	0.303	0.267	0.199	0.133	0.262	0.283	0.242	0.199	0.202	0.202	0.288	0.382	0.313	0.292	0.413	0.0921	0.396	0.189	0.254	0.183	0.15	0.19	0.279	0.213	0.253	0.203	0.23	0.21	0.214	0.111	0.375	0.275	0.241	0.182	0.729	0.219	0.314	0.168	0.229	0.164	0.234	0.188	0.181
AEA	1.06	1.14	1.54	1.88	1.53	1.42	1.45	1.48	1.48	0.856	1.23	1.06	1.16	1.72	1.66	0.812	0.529	1.27	1.57	1.71	1.42	2.33	1.62	1.07	2.35	1.86	1.76	1.35	1.15	0.975	1.47	1.05	0.923	1.74	1.38	1.45	1.62	1.02	1.1	1.31	1.02	1.74	0.963	1.24	1.88	1.55	0.808	0.667	2.02	1.01	1.34	0.95	1.1	0.737	0.597	1.37	1.34	1.74	0.64	2.45	0.964	1.44	1.36	0.794	1.65	0.848	1.21	0.766	1.45	0.967	1.26	1.74	1.68	1.56	2.01	0.72	1.77	1.93	1.92	2.08	0.913	1.31	1.18	1.56	1.47	1.01	1.32	1.27	1.52	0.805	1.29	1.51	1.73	1.98	0.797	1.34	1.32	1.12	1.38	1.11	1.39	0.785	0.929	1.05	1.38	1.28	1.32	1.41	1.93	1.09	0.767	1.42	0.872	1.26	1.4	1.12	1.47	1.5	0.906	0.876	1.27	1.35	1.13	1.05	0.867	2.52	1.18	0.848	1.2	2.82	1.62	1.14	0.576	1.76	1.32	0.678	1.11	0.858
DEA	0.734	0.712	0.557	0.707	0.979	0.685	0.849	1.19	1.38	0.522	0.567	0.514	0.662	0.879	0.79	0.565	0.418	1.44	1.12	0.671	0.892	1.42	1.12	1.03	1.32	0.669	0.699	0.491	1.01	0.445	0.849	0.389	0.75	0.909	0.669	0.571	1.09	0.455	0.449	1.12	0.519	0.868	0.869	0.579	1.15	0.529	0.632	0.332	0.911	0.279	0.752	0.881	0.516	0.352	0.298	0.489	0.492	1.47	0.485	1.07	0.783	0.762	0.979	0.379	0.637	0.344	0.895	0.393	1.8	0.552	1.14	0.823	0.837	0.981	1.31	0.424	1.26	1.18	1.21	0.555	0.887	0.533	0.621	1.4	1.21	0.949	0.605	1.09	0.664	0.454	0.622	1.2	0.89	0.97	0.933	0.643	0.328	0.61	1.04	0.771	0.43	0.679	0.551	0.832	0.642	0.927	0.911	0.797	0.944	0.349	0.603	0.907	0.664	0.561	0.587	0.582	0.547	0.951	0.723	0.465	0.46	0.824	0.76	1.17	0.484	1.86	0.933	0.379	0.671	1.47	1.09	0.764	0.476	1.58	1.09	0.498	1.04	0.803
DHEA	1	0.976	1.21	1.76	0.704	0.812	0.909	1.76	0.994	0.827	1.02	0.832	1.06	0.975	0.846	0.777	0.538	0.645	1.23	0.88	0.987	1.52	1.44	0.427	1.43	1.12	1.08	0.662	0.562	0.903	0.845	0.65	0.866	1.25	1.78	0.817	1.17	1.17	0.81	0.767	1.56	1.15	0.813	1.14	0.802	1.18	1.12	0.573	1.17	1.48	1.36	0.447	0.964	0.91	0.871	0.833	0.956	1.43	0.853	2.16	0.758	1.24	1.07	1.03	1.28	1.54	0.97	1.23	0.689	1.02	0.591	2.37	0.877	0.636	1.14	0.663	0.745	1.01	0.999	1.27	0.814	1.3	0.642	0.656	1.2	0.587	2.2	0.664	1.35	0.654	0.421	0.818	0.93	0.964	0.685	1.36	0.803	1.69	1.29	0.815	1.37	0.542	0.442	0.459	2.31	0.424	1.73	1.13	1.07	1.58	0.492	1.18	0.835	0.885	1.14	0.817	1.04	1.47	0.611	0.928	0.998	1.21	0.309	0.574	0.537	1.4	0.947	0.575	1.02	1.63	1.49	1.69	0.553	0.842	1.06	1.06	0.495	0.576
NO-Gly	2	0.634	1.51	1.54	1.25	1.79	1.23	1.54	1.39	1.59	1.85	1.84	1.33	1.78	1.39	0.865	0.678	1.15	1.8	0.835	1.92	1.76	1.14	1.43	2.93	1.76	1.95	1.79	1.51	2.07	1.57	1.75	1.32	2.01	2.25	1.34	2.15	1.6	1.81	1.35	1.19	1.73	1.24	1.92	0.885	2.39	2.3	0.911	3.26	1.72	1.26	0.724	0.942	1.46	1.99	0.973	1.39	2.78	1.32	2.69	0.898	1.96	2.22	1.4	1.53	1.65	1.21	1.69	1.95	1.24	1.69	1.72	1.15	1.63	2.02	0.983	0.972	0.862	2.42	1.51	2.85	2.25	1.02	1.9	3.25	1.47	1.7	1.81	2.27	2.38	2.95	2.8	4.36	2.76	1.23	4.76	1.03	2.42	1.82	1.64	1.58	1.85	3.93	2	1.99	3.07	1.72	4.42	2.88	1.93	1.21	2.9	5.41	2.23	2.09	2.04	1.42	0.943	2.89	1.78	0.798	1.58	1.98	2.99	0.807	1.96	2.73	1.13	2.18	2.45	2.79	1.39	1.02	2.39	2.47	1.81	0.99	2.07
NA-Gly	0.888	0.275	0.545	0.593	0.349	2.71	0.376	1.09	0.47	0.476	0.65	0.647	0.501	0.463	1.17	0.334	0.693	0.788	0.864	0.395	0.866	1.49	0.884	0.958	0.469	0.44	0.57	1.37	0.847	0.639	0.566	2.6	0.506	1.48	0.795	1.08	2.16	0.391	1.79	0.784	0.281	1.56	0.494	0.355	0.424	1.75	0.435	0.658	0.431	0.274	1.79	0.516	0.337	0.286	0.28	0.42	0.228	1.71	0.456	0.916	0.445	1.89	0.848	0.437	0.765	0.579	0.613	0.389	0.663	1.47	0.795	0.29	0.512	0.274	0.71	0.658	0.247	0.735	1.1	0.326	1.98	1.52	0.509	0.729	0.675	0.588	0.237	0.385	1	0.728	0.99	0.941	1.69	0.773	0.218	1.17	0.281	0.332	0.736	0.412	0.491	0.197	0.783	0.528	0.469	0.795	1.45	2.32	0.846	0.235	0.327	0.623	0.46	0.186	0.909	0.34	0.572	0.505	0.28	0.804	0.147	0.195	0.749	0.762	0.169	0.576	0.313	0.629	0.552	0.318	0.528	0.29	0.204	1.1	0.622	0.616	0.389	0.723
2-OG	232	312	190	899	197	617	158	434	436	163	373	593	174	286	473	468	242	837	1930	194	162	310	439	273	306	643	178	678	568	752	415	493	1410	136	89.7	481	223	150	409	195	1920	206	203	313	238	1180	174	469	454	1210	181	232	340	491	192	110	520	178	807	177	201	112	785	460	80	428	641	811	331	111	1820	1220	437	183	623	525	145	338	638	676	892	270	1020	272	264	373	998	226	899	484	999	234	950	206	132	889	344	284	249	839	972	195	1300	465	1240	911	308	201	654	416	199	688	209	548	151	109	451	383	187	676	264	155	311	216	284	174	326	203	409	523	153	1010	150	266	355	407	250	500
1-OG	297	382	434	1220	528	1170	369	641	954	310	478	718	472	627	1070	507	426	1240	1960	196	222	565	828	337	437	532	196	810	1020	929	518	758	2380	194	147	861	223	221	461	387	2360	353	386	386	311	839	261	819	299	1090	245	477	313	557	348	115	672	299	936	147	273	193	942	429	94.9	588	762	928	854	146	1600	896	394	243	450	602	266	541	638	660	1080	173	1050	485	442	820	1600	482	1630	746	1060	640	1760	436	556	1080	667	687	386	1390	1280	400	1740	803	1720	1170	527	308	1700	737	367	911	274	1160	209	218	570	455	314	720	350	290	407	409	513	292	558	377	604	867	338	1190	220	489	555	887	493	859
2-LG	144	111	67.7	267	31.9	156	79	72.6	95.9	78.3	100	171	108	106	308	140	112	154	775	109	35.7	96.1	212	62.6	112	346	64.2	202	268	280	121	221	182	82.1	54.8	174	23.8	92	216	33.1	702	128	96.9	58.1	39.2	702	101	238	141	414	109	72.3	177	175	122	45.2	123	23.8	328	60.2	127	37.2	282	124	30.6	92.9	158	141	84.3	31.3	584	451	247	76.5	180	178	49.6	148	166	365	347	66.7	392	61.1	141	232	491	120	542	319	378	124	664	105	74.7	551	236	148	144	328	513	80.6	1090	161	795	221	67	39.4	375	235	145	121	171	101	64.5	88.3	182	87.5	65.9	335	100	49.1	49.5	75	134	58.2	143	119	254	102	66.3	404	55.9	139	156	259	87.8	276
1-LG	343	241	265	749	287	923	373	389	448	392	512	510	668	415	1190	302	531	1020	1690	203	271	688	1160	168	384	607	135	705	685	540	646	802	1210	188	219	622	162	238	420	371	2340	455	380	464	153	805	372	950	399	936	307	399	414	720	259	117	472	144	625	223	284	178	566	335	102	484	556	749	682	115	1790	865	648	244	425	613	164	419	641	345	1200	122	788	251	421	807	1120	611	1200	615	387	392	1150	225	432	782	477	431	318	925	794	217	1730	599	1390	524	222	116	1820	449	400	606	323	571	115	276	432	336	301	963	374	195	160	418	313	220	387	235	337	400	305	631	136	299	521	698	287	1000
2-AG	15.6	13.9	6.61	38.8	9.64	24.4	13.3	30.1	14.8	12.5	22.2	24.4	9.15	17.8	26.3	22.4	16.9	57.7	128	12.1	5.68	28	37.1	17.2	17.8	22.8	10.3	28.3	50.2	30.3	16.2	30.9	78.5	11.1	4.25	22.4	11.6	13.5	29	17.4	137	24.8	19.9	17.5	10.7	87.6	11.8	16.9	22.9	38.8	18.2	25.2	25.1	30.9	11	8.1	35	5.46	57.2	8.46	13.3	14.4	27.7	21.3	4.89	27.4	23.9	24.6	22.3	8.4	69.5	109	21.1	15.8	31.8	24.3	11.4	26.8	40.5	19.9	35.5	10.8	39.6	9.59	13.3	22.2	74.9	13.7	59.1	22.3	30.8	12.9	63	9.71	6.9	37.4	17.8	14.8	18.1	27.5	38.7	11	49.8	17.7	74.9	23.3	17	8.82	44.5	12.9	13.1	16.9	11.5	20	6.44	9.82	18.5	26.8	17.2	74.9	15.2	7.49	20.8	21.5	25.7	16	30.4	13.7	51.6	20.1	16.9	38.6	10.5	36.9	18.4	43.5	17.4	33.6
1-AG	17	18.3	10.2	55.5	18.7	64.1	16.9	48.4	29.6	30	27.7	22.5	17.1	22.2	57.5	20.7	21.3	78.2	120	12.9	13.6	45.6	57.1	17.6	23.5	20.2	8.91	25.1	63	31.3	18.1	41.1	151	12.9	7.09	29.4	13.3	30.8	23.1	28.2	137	32.9	25.6	14.9	12.7	52.4	16.2	24.2	19.9	38	15.3	35.9	21.6	28.1	11	7.61	33	12.4	48.8	6.69	11.1	13.1	35.4	16.9	6.44	20.5	21.4	34.2	39.7	7.26	71.5	52.8	15.3	14.9	21.6	21.6	12.3	36.1	34.4	16.8	49.5	7.14	28.8	15.8	27.6	43.2	91.5	30.6	101	37.6	40.4	35.4	57.4	27.9	19.5	56.3	32.2	23.2	29.2	41.4	54.6	16.6	76.5	34.4	89.1	33.3	24.4	10.9	98.7	25.4	18.8	24.4	14.5	46.2	7.79	18.9	21.3	24.5	25.4	63.4	28.7	10.8	22.5	31.8	32.7	22.6	33.9	16.1	48	42	44.9	54.8	11.5	53.1	25.1	62.7	33.2	42
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	HMDB ID	InChIKey	PubChem CID	KEGG
LEA	HMDB12252	KQXDGUVSAAQARU-HZJYTTRNSA-N	5283446
aLEA	HMDB13624	HBJXRRXWHSHZPU-PDBXOOCHSA-N	5283449
DGLEA	HMDB13625	ULQWKETUACYZLI-QNEBEIHSSA-N	5282272	C13828
AEA	HMDB04080	LGEQQWMQCRIYKG-DOFZRALJSA-N	5281969	C11695
DEA	HMDB13626	FMVHVRYFQIXOAF-DOFZRALJSA-N	5282273	C13829
DHEA	HMDB13627	CXWASNUDKUTFPQ-KUBAVDMBSA-N	53245830
NO-Gly	HMDB13631	HPFXACZRFJDURI-KTKRTIGZSA-N	6436908
NA-Gly	HMDB05096	YLEARPUNMCCKMP-DOFZRALJSA-N	5283389
2-OG	HMDB11537	UPWGQKDVAURUGE-KTKRTIGZSA-N	5319879
1-OG	HMDB11567	RZRNAYUHWVFMIP-QJRAZLAKSA-N	12178130
2-LG	HMDB11538	IEPGNWMPIFDNSD-HZJYTTRNSA-N	5365676
1-LG	HMDB11568	WECGLUPZRHILCT-GSNKCQISSA-N	6436630
2-AG	HMDB04666	RCRCTBLIHCHWDZ-DOFZRALJSA-N	5282280
1-AG	HMDB11578	DCPCOKIYJYGMDN-HUDVFFLJSA-N	16019980
METABOLITES_END
#END
